Pulmonary physiology in interstitial lung disease: Recent developments in diagnostic and prognostic implications

Current Opinion in Pulmonary Medicine

Volumn 2, Issue 5, 1996, Pages 370-375

  Baydur, Ahmet ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; DIAGNOSTIC AGENT;

AIRWAY RESISTANCE; BIOPSY; BREATHING MECHANICS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOLOGY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG; LUNG COMPLIANCE; LUNG DIFFUSION CAPACITY; LUNG LAVAGE; LUNG VENTILATION; LUNG VOLUME; LYMPHOCYTE COUNT; MALE; PATHOPHYSIOLOGY; PEAK EXPIRATORY FLOW; PHYSIOLOGY; PROGNOSIS; RADIOGRAPHY; REVIEW; SEX DIFFERENCE; TIDAL VOLUME; VITAL CAPACITY;

AIRWAY RESISTANCE; BIOPSY; BRONCHOALVEOLAR LAVAGE FLUID; CARBON MONOXIDE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; LUNG COMPLIANCE; LUNG DISEASES, INTERSTITIAL; LUNG DISEASES, OBSTRUCTIVE; LUNG VOLUME MEASUREMENTS; LYMPHOCYTE COUNT; MALE; PEAK EXPIRATORY FLOW RATE; PROGNOSIS; PULMONARY DIFFUSING CAPACITY; PULMONARY VENTILATION; RESPIRATORY MECHANICS; SEX FACTORS; TIDAL VOLUME; VITAL CAPACITY;

EID: 0030224431     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199609000-00005     Document Type: Article

References (48)

1. Fulmer JD, Roberts WC, Crystal RG: Diffuse fibrotic lung disease: a correlative study. Chest 1976, 69(suppl):263-265.
2. Todisco T, Matthys H, Cegla UH: Clinical determination of airway closure, comparison of three methods in patients with lung fibrosis. Respiration 1977, 34:197-204.
3. Tan CSH, Tashkin DP: Supernormal maximal midexpiratory flow rates in diffuse interstitial lung disease. Respiration 1981, 42:141-149.
4. Kanengiser LC, Rapoport DM, Epstein H, Goldring R: Volume adjustment of mechanics and diffusion in interstitial lung disease: lack of clinical relevance. Chest 1989, 96:1036-1042.
5. Lahdensuo A, Korpela M: Pulmonary findings in patients with primary Sjögren's syndrome. Chest 1995, 108:316-319. The authors found pulmonary hyperinflation in nine of 17 patients with Sjögren's syndrome. The higher the values of TLC and functional residual capacity, the lower were the maximum expired flow at 50% of vital capacity measurements and the more dyspnea occurred in patients. Such findings suggest the development of small airways disease, such as a mild proliferative bronchiolitis obliterans, in patients with certain vasculitides involving the lung, as also described in rheumatoid arthritis.
6. Lahdensuo A, Mattila J, Vilppula A: Bronchiolitis in rheumatoid arthritis. Chest 1984, 85:705-708.
7. Dayton CS, Schwartz DA, Sprince NL, Yagla SJ, Davis CS, Koechnke RK, Furst DE, Hunninghake GW: Low-dose methotrexate may cause air trapping in patients with rheumatoid arthritis. Am J Respir Dis 1995, 151:1189-1193.
8. Beinert T, Behr J, Mehnert F, Kohz P, Seemann M, Rienmüller R, Reiser M: Spirometrically controlled quantitative CT for assessing diffuse parenchymal lung disease. J Comput Assist Tomogr 1995, 19:924-931. In this prospective study, 27 patients with chronic disease (16 with IPF, 11 with COPD) who underwent HRCT were compared with 24 normal subjects. HCRT was performed at three degrees of lung inflation standardized by spirometry. Discriminatory power for lung density was best among all cohorts at mid-lung volume, which appeared to provide a compromise between compressive changes near respiratory volume and poor density discrimination near TLC.
9. Jayamanne DS, Epstein H, Goldring RM: The influence of lung volume on expiratory flow rates in diffuse interstitial lung disease. Am J Med Sci 1978, 275:329-336.
10. Fulmer JD, Roberts WC, Von Gal ER, Crystal RG: Small airways in idiopathic pulmonary fibrosis. J Clin Invest 1977, 60:595-610.
11. Gaultier G, Chaussain M, Boule M, Buvry A, Allaire Y, Perret L, Girard F: Lung function in interstitial lung diseases in children. Bull Eur Physiolopathol Respir 1980, 16:57-66.
12. Murphy DMF, Hall DR, Petersen MR, Lapp NL: The effect of diffuse pulmonary fibrosis on lung mechanics. Bull Eur Physiopathol Respir 1981, 17:27-41.
13. Bernasconi M, Ploysongsang Y, Gottfried SB, Milic-Emili J, Rossi A: Respiratory compliance and resistance in mechanically ventilated patients with acute respiratory failure. Intensive Care Med 1988, 14:547-553.
14. Tantucci C, Corbeil C, Chasse M, Robatto FM, Nava S, Braidy J, Matar M, Milic-Emili J: Flow and volume dependence of respiratory system flow resistance in patients with adult respiratory distress syndrome. Am Rev Respir Dis 1992, 145:355-360.
15. Koulouris NG, Valta P, Lavoie A, Corbeil C, Chassé M, Brady J, Milic-Emili J: A simple method to detect expiratory flow limitation during spontaneous breathing. Eur Respir J 1995, 8:306-313.
16. Valta P, Campodonico R, Corbeil C, Chassé M, Chatillon A, Brady J, Matar N, Milic-Emili J: Detection of expiratory flow limitation during mechanical ventilation. Intensive Care Med 1992, 18(suppl 2):S214.
17. Epler GR, McLoud TC, Gaensler EA, Mikus JP, Carrington CB: Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N Engl J Med 1978, 298:934-939.
18. American Thoracic Society: Single breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique. Am Rev Respir Dis 1987, 186:1299-1307.
19. Beck KC, Offord KP, Scanlon PD: Comparison of four methods for calculating diffusing capacity by the single breath method. Chest 1994, 105:594-600.
20. Mönkáre S, Ikonnen M, Haahtela T: Radiologic findings in farmer's lung: prognosis and correlation to lung function. Chest 1985, 87:465-466.
21. Hapke EJ, Seal RME, Thomas GO: Farmer's lung: a clinical, radiographic and serological correlation of acute and chronic stages. Thorax 1968, 23:451-468.
22. Nugent KM, Peterson MW, Jolles H, Monick MM, Hunninghake GW: Correlation of chest roentgenograms with pulmonary function and bronchoalveolar lavage in interstitial lung disease. Chest 1989, 96:1224-1227.
23. Sietsema KE, Kraft M, Ginzton L, Sharma OP: Abnormal oxygen uptake responses to exercise in patients with mild pulmonary sarcoidosis. Chest 1992, 102:838-845.
24. Renzi G, Milic-Emili J, Grassino AE: The pattern of breathing in diffuse lung fibrosis. Bull Eur Physiopathol Respir 1982, 18:461-472.
25. Gorini M, Ginnanni R, Spinelli A, Duranti R, Andreotti L, Scano G: Inspiratory muscle strength and respiratory drive in patients with rheumatoid arthritis. Am Rev Respir Dis 1990, 142:289-294.
26. Baydur A, Pandya K, Sharma OP, Kanel GC, Carlson M: Control of ventilation, respiratory muscle strength and granulomatous involvement of skeletal muscle in patients with sarcoidosis, Chest 1993, 103:396-402.
27. Spinelli A, Marconi G, Gorini M, Pizza A, Scano G: Control of breathing in patients with myasthenia gravis. Am Rev Respir Dis 1992, 145:1359-1366.
28. De Troyer A, Estenne M: The respiratory system in neuromuscular disorders. In The Thorax. Part C. Disease, edn 2. Edited by Roussos C. New York: Marcel Dekker; 1995:2177-2212.
29. Eisenberg H: The interstitial lung disease associated with the collagen-vascular disorders. Clin Chest Med 1982, 3:565-578.
30. Scano G, Goti P, Duranti R, Misuri G, Emmi L, Rosi E: Control of breathing in a subset of patients with systemic lupus erythematosus. Chest 1995, 108:759-766.
31. Banzett RB, Mead J: Reflex compensation for changes in operational length of inspiratory muscles. In the Thorax. Part C. Disease, edn 2. Edited by Roussos C, Macklem PT. New York: Marcel Dekker; 1985:595-605.
32. Harris-Eze AO, Sridhar G, Clemens RE, Zintel JA, Gallagher CG, Marciniuk DD: Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med 1995, 152:1940-1945.
33. Woodcock AA, Gross ER, Gellert A, Shah S, Johnson M, Geddes DM: Effects of dihydrocodeine, alcohol and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med 1981, 305:1611-1616.
34. Light RW, Mura JR, Sato RI, Stansbury DW, Fischer CE, Brown SE: Effects of oral morphine or breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989, 139:126-133.
35. Sleijfer S, van dem Mark TW, Koops HS, Mulder NH: Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. Br J Cancer 1995, 71:120-123. Fifty-four patients with nonseminomatous tumor of the testis were randomly assigned to receive treatment with four cycles of bleomycin, etoposide, or cisplatin (27 patients) or with four cycles of etoposide or cisplatin (27 patients). VC and capillary blood volume decreased in patients receiving BEP but remained constant in those who received EP. By contrast, these authors found that the widely used DLCO was not a suitable parameter to monitor specifically pulmonary toxicity induced by bleomycin as part of a multidrug regimen. This is one of a few recent studies to describe the effects of antineoplastic agents such as bleomycin on the pulmonary endothelium rather than on alveolar cells and structure.
36. Doll DC, Yarbo JW: Vascular toxicity with neoplastic agents. Semin Oncol 1992, 19:580-596.
37. Groen HJM, van der Mark TW, van der Leest AHD, De Vries EGE, Mulder NH: Pulmonary function changes in lung-cancer patients treated with radiation with or without carboplatin. Am J Respir Crit Care Med 1995, 152:2044-2048. In this prospective study, 33 patients with locally advanced non-small-cell lung cancer underwent pulmonary function testing before, during, and after radiation and combined chemotherapy. No major short-term (at 2 and 6 months) functional effects of radiation alone on in combination with carboplatin were observed, especially of DLCO. Fixed reduction in membrane diffusing capacity and pulmonary capillary blood volume were attributed to obstruction of mediastinal vascular and lymphatic systems.
38. Smit EF, Willemse PHB, Sleijfer DT, Uges DRA, Postmus PE, Meijer S, Terheggen PMAB, Mulder NH, De Vries EGE: Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study. J Clin Oncol 1991, 9:100-110.
39. Marina NM, Greenwald CA, Fairclough DL, Thompson EI, Wilimas JA, Mackert PW, Hudson MM, Stokes DC, Bozeman PM: Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantel radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer 1995, 75:1706-1711.
40. O'Driscoll BR, Kalra S, Gattamaneni HR, Woodcock AA: Late carmustine lung fibrosis: age and treatment may influence severity and survival. Chest 1995, 107:1355-1357. In the treatment of childhood brain tumors, a younger age at the time of the treatment with carmustine appears to be associated with a higher morbidity and mortality. Carmustine is associated with delayed pulmonary fibrosis. This study suggests the developing lung is sensitive to the harmful effects of carmustine.
41. Badier M, Guillot C, Delpierre S, Vanuxem P, Biaise D, Maraninchi D: Pulmonary function changes 100 days and one year after bone marrow transplantation. Bone Marrow Transplant 1993, 12:457-461.
42. Tait RC, Burnett AK, Robertson AG, McNee S, Riyami BMS, Carter R, Stevenson RD: Subclinical pulmonary function defects following antologous and allogeneic bone marrow transplantation: relationship to total body irradiation and graft-versus-host disease. Int J Radiat Oncol Biol Phys 1991, 20:1219-1227.
43. Lund MS, Kongerud J, Brinch L, Evensen SA, Boe J: Decreased lung function in one year survivors of allogeneic bone marrow transplantation conditioned with high-dose busulphan and cyclophosphamide. Eur Respir J 1995, 8:1269-1274. In this prospective study, 43 patients underwent evaluation prior to, 3 months after, and 1 year after receiving bone marrow transplantation. In the majority of patients, lung volumes decreased by nearly 10% within 3 months but returned to baseline values 1 year later. DLCO dropped by 24% after 3 months and remained 13% below pretreatment levels after 1 year. Smoking contributed to more severe and persistent changes in the DLCO, suggesting that it sensitizes the lung for cytotoxic injury or that high-dose chemotherapy made the the lungs more susceptible to smoking-induced damage.
44. Wong MK, Bjarnason JA, Hrushesky WJ, Webster P, Izabella M-P, Towers M: Steroid-responsive interstitial lung disease in patients receiving 2'-deoxy-5-fluorouridine-infusion chemotherapy. Cancer 1995, 75:2558-2564.
45. Clark JG, Crawford SW, Madtes DK, Sullivan KV: Obstructive lung disease after allogeneic marrow transplantation: clinical presentation and course. Ann Intern Med 1989, 111:368-376.
46. Crawford SW, Pepe M, Lin D, Benedetti F, Deeg HJ: Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality. Am J Respir Crit Care Med 1995, 152:690-695. In this prospective nonrandomized study in a tertiary referral center, close to 1000 patients who had undergone bone marrow transplantation were investigated for the clinical significance of declines in pulmonary function 3 months after marrow transplantation. The authors found an increase in the nonrelapse mortality rate associated with either the presence of a restrictive defect 3 months after transplantation or a significant decline in lung volume compared with baseline. The effect was most prominent more than 1 year after transplantation and resulted from an increase in the rate of death with respiratory failure.
47. 2 from cultured alveolar macrophages. Higher concentrations of lymphocytes in the bronchoalveolar lavage fluid appeared to be associated with slightly improved survival.
48. Hanson D, Winterbauer RH, Kirtland SH, Wu R: Changes in pulmonary function test results after one year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995, 108:305-310. Fifty-eight patients with IPF were studied over a 21-year period to determine whether changes in pulmonary function were predictive of survival. The authors found that patients with an increased or unchanged FVC and/or increased or unchanged DLCO after 1 year of treatment gain a statistically significant survival benefit over those with decreases in the same lung functions.